What is going to happen to Dendreon and Provenge?

According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that sipuleucel-T (Provenge) will almost certainly continue to be available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

The only named bidder at this time is Valeant, which has raised its bid to  $400 million from an initial $296 million. The deadline for parties to submit bids to Dendreon is February 10, with an auction to be held on February 12 if Dendreon receives other offers.

3 Responses

  1. What do you say we partner on this Mike? I can write a check…

  2. I’m good for about $5.00!

  3. Valeant prevailed at $400 million after second bidder dropped out. Valeant is an aggressive company known for cost cutting. Deal should close by end of February.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: